Future studies should clarify EA’s direct role in tubulin dynamics, its influence on the IL-17 pathway, on established mechanisms of drug resistance, such as MGMT promoter methylation status, DNA repair pathways, or efflux transporter activity in primary patient-derived cells, as well as in vivo, for example, in genetically engineered glioma models (GEGMs) or orthotopic animal models including pharmacodynamic and pharmacokinetic evaluations to explore clinical translation of EA-TMZ combinations. Here, MGMT is linked to glioma.